Search Results
Scott Kopetz, MD, PhD, FACP, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC
Dr. Kopetz on the Rationale for the BEACON CRC Study in BRAF V600E-Mutant mCRC
Dr. Kopetz on the Rationale and Primary Endpoints of the BEACON CRC Study in mCRC
Dr. Kopetz on Safety Data From BEACON CRC Trial in BRAF V600E-Mutant mCRC
Dr. Kopetz on the Biology of Right- Versus Left-Sided CRC
Winship Grand Rounds: March 24, 2021 - Scott Kopetz, MD, PhD, FACP
Scott Kopetz, MD, PhD, FACP, discusses the incidence of BRAF mutation in CRC patients
Real-World Management of Patients with BRAF-V600E mCRC
Scott Kopetz, MD, PhD, FACP, on the potential of binimetinib + immunotherapy in mCRC patients
Updated Survival Data from BEACON CRC Lead to More Specific Questions
Dr. Eng Discusses the BEACON CRC Study in BRAF-Mutated CRC
Scott Kopetz, MD, PhD, FACP, regarding molecular profile matching in trials with mCRC patients
